# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion

> **NCT07487545** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 52 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SSS67 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07487545
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2026-08-29
- **Final completion:** 2027-04-02
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487545, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07487545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*